Primary and Metastatic Brain Tumours Assessed with the Brain and Torso [¹⁸F]FDG PET/CT Study Protocol-10 Years of Single-Institutional Experiences

• मुख्य लेखकों: Agata Pietrzak (लेखक), Andrzej Marszałek (लेखक), Tomasz Piotrowski (लेखक), Adrianna Medak (लेखक), Katarzyna Pietrasz (लेखक), Julia Wojtowicz (लेखक), Hubert Szweda (लेखक), Krzysztof Matuszewski (लेखक), Witold Cholewiński (लेखक)
• स्वरूप: पुस्तक
• प्रकाशित: MDPI AG, 2021-07-01T00:00:00Z.
• विषय: article
• ऑनलाइन पहुंच: Connect to this object online.
• Notes: 10.3390/ph14080722; 1424-8247
• Keywords: brain tumour; ¹⁸F-fluorodeoxyglucose; oncology; positron emission tomography; Medicine; R; Pharmacy and materia medica; RS1-441
• Source: Pharmaceuticals, Vol 14, Iss 8, p 722 (2021)

According to the international societies' recommendations, the 2-deoxy-2-[¹⁸F]fluoro-D-glucose positron emission tomography/computed tomography ([¹⁸F]FDG PET/CT) technique should not be used as the method of choice in brain tumour diagnosis. Therefore, the brain region can be omitted during standard [¹⁸F]FDG PET/CT scanning. We performed comprehensive literature research and analysed results from 14,222 brain and torso [¹⁸F]FDG PET/CT studies collected in 2010-2020. We found 131 clinically silent primary and metastatic brain tumours and 24 benign lesions. We concluded that the brain and torso [¹⁸F]FDG PET/CT study provides valuable data that may support therapeutic management by detecting clinically silent primary and metastatic brain tumours.